




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : G01N 33/48		A1	(11) International Publication Number: WO 91/19977
			(43) International Publication Date: 26 December 1991 (26.12.91)
(21) International Application Number: PCT/US91/04132 (22) International Filing Date: 17 June 1991 (17.06.91) (30) Priority data: 539,999 15 June 1990 (15.06.90) US (71) Applicant: UNITED STATES DEPARTMENT OF ENERGY [US/US]; 1000 Independence Avenue, S.W., Washington, DC 20585 (US). (72) Inventors: COLE, Dean, A. ; 60 San Juan Street, Los Alamos, NM 87544 (US). MOODY, David, C., III ; 402 Pine Tree Lane, Boulder, CO 80304 (US). ELLINWOOD, L., Edward ; 694 Sperber Lane, Grand Junction, CO 81506 (US). KLEIN, M., Gerard ; 715 Victor Drive, Grand Junction, CO 81506 (US). (74) Agents: CONSTANT, Richard, E. et al. Assistant General Counsel for Intellectual Property; United States Department of Energy, GC-42 (FORSTL) MS 6F-067, 1000 Independence Avenue, S.W., Washington, DC 20585 (US).		(81) Designated States: AT (European patent), AU, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH (European patent), CI (OAPI patent), CM (OAPI patent), DE (European patent), DK, DK (European patent), ES (European patent), FI, FR (European patent), GA (OAPI patent), GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European patent), JP, KR, LK, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL (European patent), NO, RO, SD, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent). Published With international search report.	

(54) Title: USING 5,10,15,20-TETRAKIS(r-CARBOXYPHENYL)PORPHINE FOR DETECTING AND TREATING LUNG CANCER



(57) Abstract

Method using tetra-aryl porphyrins for and, in particular, 5,10,15,20-tetrakis(4-carboxyphenyl)porphine as a fluorescent tracer for cancers of the lung, and as a radiotracer therefor as a complex with ⁶⁷Cu. The latter complex also provides a source of beta radiation for selective destruction of lung malignancies as well as gamma radiation useful for image analysis of the situs thereof by single photon emission computed tomography, as an example, both *in vivo*. Copper-64 may be substituted for the ⁶⁷Cu if only radiotracer characteristics are of interest. This lighter isotope of copper is a positron emitter, and positron emission tomography techniques can be used to locate the malignant tissue mass.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

-1-

Using 5, 10, 15, 20-Tetrakis (r-Carboxyphenyl)
Porphine for Detecting and Treating Lung Cancer.

BACKGROUND OF THE INVENTION

The present invention relates generally to the use of porphyrins to detect lung cancer, and more particularly to the use of tetra-aryl porphyrins, of which 5,10,15,20-tetrakis(4-carboxyphenyl)porphine is an example, to detect and treat lung cancer. This invention is the result of Contract No. W-7405-ENG-36 between the Regents of the University of California and the U.S. Department of Energy.

Cancer of the lung is a major world health problem and remains untreatable. It has been determined that in 1986 malignant lesions of the lung killed more than three times as many men as cancer of the colon and surpassed breast cancer as the major lethal malignant disease in women. Despite an enormous commitment of resources during the past decade, the success in the management of lung cancer has been minimal at best. In fact, in 1988, the annual death rate for lung cancer in the United States was estimated to approach 110,000 deaths. In addition, 150,000 new cases of lung cancer were diagnosed in 1988, making lung cancer the number one cancer killer. Attempts at mass-screening high risk populations have also been unsuccessful.

The treatment of lung cancer has largely been unsuccessful and at times controversial. The overall five-year survival for a patient with lung cancer still remains less than 10%. The practice of surgically resecting the tumor is the most successful of all

treatments; however, in most cases the malignant lesions recur or metastasize. The use of radiotherapy and chemotherapy have also had limited success in prolonging the life of lung cancer patients. In fact, the median
05 survival for a patient with small cell lung carcinoma, who is treated with chemotherapy and with or without radiation therapy is 10-15 months in patients with "limited" disease, and 7-11 months in patients with "extensive" disease.

The association between lung cancer and cigarette smoke
10 is well established; however, other environmental factors also play a role in the etiology of lung cancer. One of these environmental agents is radon-222, a noble gas that is ubiquitous in the natural environment, is created by the decay of radium, which is in turn derived from the decay of
15 uranium. Uranium is present in the earth's crust throughout the world. Radon gas forms in the earth's surface during uranium decay and diffuses into the atmosphere, where it becomes a health hazard. When radon decays in the atmosphere, its short-lived radioactive
20 daughters (isotopes of polonium, bismuth, and lead) attach themselves to dust particles in the air. These radioactive particles as well as unattached radon daughters are then inhaled into the lungs. Radon and radon daughters give off alpha, beta, and gamma radiation. It is estimated that
25 radon daughters deliver over 95% of the alpha radiation dose to the basal cells in the tracheobronchial epithelium of the lung.

Epidemiologic evidence has determined that exposure to radon and its daughters results in an increased risk of
30 bronchial carcinoma. In the early 60's, cytological techniques were developed to detect lung cancer in uranium miners, who, through multiple processes, are exposed to significant radon and radon daughter inhalation applied to the bronchial epithelium over a period of many years. It

has been demonstrated further that the incidence of lung cancer in miners who smoke cigarettes is ten times greater than miners who did not smoke. These pulmonary cytopathology techniques have proven to be a very sensitive procedure for detecting abnormal/cancerous cells in high risk populations, such as uranium miners; however, once neoplastic cells have been identified, the task of localizing the occult carcinoma in the lung can be difficult, and in many cases an impossible problem. Because most in situ lesions cannot be seen with the unaided eye, such lesions must be localized by selective bronchial brushing and blind spur biopsies. These diagnostic procedures require general anesthesia and at least 2-3 hours to perform. The location of such early neoplastic lesions is of significant importance for the treatment of lung cancer. It is believed by many that for the treatment of lung cancer to be successful, the treatment procedure must be started at an early stage of cancer development (in situ). To successfully detect these early malignant lung lesions, new compounds must be developed which can be used in routine clinical procedures to detect small lung lesions.

Porphyrins and, in particular, hematoporphyrin derivative have been known for many years to have a significant affinity for malignant cancer cells, and have been demonstrated to be useful as diagnostic markers. Tumor cells that have taken up hematoporphyrin fluoresce when illuminated with uv light. However, the specificity of uptake of the porphyrins used in the past has not been as complete as desirable; that is, there is a substantial background of fluorescence from noncancerous cells accompanying the fluorescence from the cells of interest. Hematoporphyrin derivative has been used more recently for the imaging of neoplastic invasion of the bladder in

humans. The procedure involves endoscopic exploration of the suspected tumor site with instrumentation that will detect fluorescent emission arising from the excitation of porphyrins with 400 nm light.

05 Porphyrins have also been used in the diagnosis and
localization of small radiologically occult lung tumors
(D. A. Cortese et al., "Hematoporphyrin Derivative In The
Detection And Localization Of Radiographically Occult Lung
Cancer," Am. Rev. Respir. Dis. 126, 1087 (1982); H. Kato et
10 al., "Early Detection Of Lung Cancer By Means Of
Hematoporphyrin Derivative Fluorescence And Laser
Photoradiation," Clin. Chest Med. 6, 237 (1985). In these
studies, a photoelectric fluorescence detection system in
combination with a conventional bronchoscope was used to
15 identify and localize early squamous cell carcinomas in
patients with normal chest radiographs. K. B. Patel et
al., "Fluorescing Cells In Sputum After Parenteral HPD," in
Progress In Clinical And Biological Research, Vol. 170, D.
Doiron and C. Gomer, Eds.; "Porphyrin Localization And
20 Treatment Of Tumors," pp. 521-530 (1984) have also
demonstrated that malignant cells could be detected in
sputum samples from lung cancer patients injected with
hematoporphyrin derivative. In this study, malignant cells
as well as some nonmalignant cells fluoresced up to 9 days
25 following the intravenous injection of the porphyrin. The
uptake of porphyrin in normal cells is not unusual because
other tissues, such as embryonic and traumatized tissues
have also been reported to localize hematoporphyrin
derivative.

30 The localization of malignant lesions using the
procedures described above is dependent upon the visual
detection of the red fluorescent emission of the
porphyrin. In most procedures, this is accomplished by
scanning the lung with a bronchoscope adapted to emit light

at a wavelength (400 nm) which will excite the porphyrin molecules. The limiting factor with this procedure is that it is time consuming and requires highly trained personnel to examine all areas of the lung for malignant lesions. 05 Because the fluorescent emission from these small lesions is so weak and difficult to observe, small lesions can easily be missed. In addition, to visually detect porphyrin fluorescence, the porphyrin must be on the surface of the tumor and the tumor must lie on the surface 10 of the lung. Any material, such as mucous covering, or the situation where a tumor is deep-seated, interferes with the overlying detection of porphyrin fluorescence. As a result, porphyrins have not been used successfully as a diagnostic tool for occult lung lesions.

15 Accordingly, it is an object of the present invention to provide a method for locating small occult malignant tumor masses in the lungs of patients.

Another object of our invention is to provide a method for selective irradiation of occult malignant tumor masses 20 in the lungs of patients.

Yet another object of the present invention is to provide a rapid, high-contrast procedure for detecting the presence of malignant cells in vitro.

Additional objects, advantages, and novel features of 25 the invention will be set forth in part in the description which follows, and in part will become apparent to those skilled in the art upon examination of the following or may be learned by practice of the invention. The objects and advantages of the invention may be realized and attained by 30 means of the instrumentalities and combinations particularly pointed out in the appended claims.

SUMMARY OF THE INVENTION

To achieve the foregoing and other objects, and in accordance with the purposes of the present invention, as

embodied and broadly described herein, the method hereof for detecting lung cancer in vitro includes producing a single cell suspension of lung cells, treating the single cell suspension of lung cells with a tetra-aryl porphyrin and, in particular, 5,10,15,20-tetrakis(4-carboxyphenyl) porphine for sufficient time to ensure significant uptake thereof by neoplastic lung cells present in the single cell suspension of lung cells, exposing the treated cell suspension with ultraviolet radiation in order to induce fluorescence in 5,10,15,20-tetrakis(4-carboxyphenyl) porphine taken up by the neoplastic cells, and evaluating the suspension for fluorescing cells.

Preferably, the single cell suspension is fixed with either carbowax and alcohol, or with paraformaldehyde.

In another aspect of the present invention, in accordance with its objects and purposes, the method for treating lung cancer, hereof includes introducing a sample of the ^{67}Cu complex of tetra-aryl porphyrin and, in particular, 5,10,15,20-tetrakis(4-carboxyphenyl)porphinato into the patient to be treated. Note that according to usual chemical terminology free-base porphyrins are termed "porphines," while complexed porphyrins bear the "porphinato" label.

In yet another aspect of our invention, in accordance with its objects and purposes, the method for locating sites of lung malignancies in vivo hereof includes introducing a sample of the ^{67}Cu or the ^{64}Cu complex of a tetra-aryl porphyrin and, in particular, 5,10,15,20-tetrakis(4-carboxyphenyl)porphinato into the patient to be treated, and performing image analysis of the emitted gamma radiation or positron emission tomography on the emitted positrons, respectively.

Benefits and advantages of the present invention include efficient, expeditious and economical

identification of lung cancer cells in sputum samples and in biopsies, by bronchoscopic investigation of lungs, and by gamma ray imaging or positron emission tomography, as well as the site-selective ionizing radiation treatment of lung cancer masses without having to apply surgical techniques.

BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying FIGURE, which is incorporated in and forms a part of the specification, illustrates an embodiment of the present invention and, together with the description, serves to explain the principles of the invention.

The FIGURE represents the structural formula for 5,10,15,20-tetrakis(4-carboxyphenyl)porphine (A), and that for the complex of this porphyrin and ^{67}Cu (B).

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS OF THE INVENTION

Briefly, the present invention includes the use of tetra-aryl porphyrins and, in particular, 5,10,15,20-tetrakis(4-carboxyphenyl)porphine (TCPP) as a fluorescent tracer for lung cancer cells, and as a radiotracer therefor as a complex with ^{67}Cu . The latter complex also provides a source of beta radiation for selective destruction of lung malignancies as well as gamma radiation useful for image analysis of the situs thereof by single photon emission computed tomography, for example. ^{64}Cu may be substituted for the ^{67}Cu if only radiotracer characteristics are of interest. The copper-64 isotope of copper is a positron emitter, and well-known positron emission tomography techniques can be used to locate the malignant tissue mass. These uses derive from the affinity TCPP and those from the same family of porphyrins have for lung malignancies when introduced into the vicinity of such cells.

Reference will now be made in detail to the present preferred embodiments of the invention, an example of which is illustrated in the accompanying Figure.

The FIGURE represents the structural formula for one
05 example of a class of tetra-aryl porphyrins which may be
used to practice the present invention, 5,10,15,20-
tetrakis(4-carboxyphenyl)porphine, TCPP, (A), and that for
the complex of this porphyrin and ^{67}Cu (B). A first
investigation was conducted to determine whether TCPP would
10 localize in neoplastic sputum cells obtained from uranium
miners, and under what conditions would this process be
maximized. A second study examined the localization of
TCPP in different types of lung cancer cells (squamous
cell, small cell, metastatic lung lymphoma, and
15 adenocarcinoma), and the ability to diagnose lung cancer in
such patients using TCPP.

A. Localization Of TCPP In Neoplastic Sputum Cells:

Five parameters were investigated for this study: (1)
the effect of various sputum processing procedures on the
20 uptake of porphyrin in sputum cells, (2) the comparison of
TCPP to three other porphyrins that are known for their
uptake by tumors, (3) the time required for optimal uptake
of the porphyrin in sputum cells, (4) the uptake of
porphyrin in test and control sputum samples, and (5) the
25 verification that TCPP was localizing in malignant sputum
cells. In each of these investigations, the uptake of
porphyrin in sputum cells was evaluated with a fluorescent
microscope. Nonmetallated porphyrin fluoresces at
approximately 650 nm. Sputum samples were evaluated for
30 (1) the number of cells in the sputum samples which
fluoresced, and (2) the intensity of the porphyrin
fluorescence.

(1) Processing Procedures:

Sputum samples require processing in order to produce a single cell suspension of lung cells. Sputum samples from test and control patients were collected and processed with alcohol and carbowax, alcohol only, phosphate buffered saline (PBS), or left unprocessed. All samples were mixed with a blender for 1 minute following the addition of the processing mixture and then placed into petri dishes containing various porphyrins. Sputum samples processed with alcohol and carbowax or alcohol (no carbowax) had a larger number of cells free of the mucous than samples processed with PBS or unprocessed samples. Cells in the unprocessed sputum samples remained attached to the bottom of the petri dish with only a few cells free of the mucous. Sputum samples processed with PBS had the greatest number of live cells when compared to sputum samples processed with alcohol or alcohol/carbowax; however, sputum cells processed with alcohol or alcohol/carbowax had the highest TCPD uptake, suggesting that TCPD may have an affinity for nonviable processed cells.

(2) Evaluation Of Different Porphyrins:

Four porphyrins selected for their known affinity for neoplastic cells were tested for their ability to detect malignant sputum cells. Sputum cells obtained from each of the four processing procedures set forth above were treated with one of hematoporphyrin derivative, HPD, 5,10,15,20-tetrakis(4-carboxyphenyl)porphine, TCPD, 5,10,15,20-tetrakis(4-sulfonatophenyl)porphine, TTPS, or uroporphyrin, URO. In all investigations, the porphyrins were dissolved in tissue culture medium at a concentration of 200 μ g/ml. Following the addition of porphyrin, each sample was incubated at 37°C for a specific length of time.

Following the incubation period, each sputum sample was examined for porphyrin uptake with a fluorescent microscope. The background fluorescence from porphyrin uptake by nonmalignant cells was lower in some measurements. Sputum samples which had been incubated with TCPP had the greatest number of cells fluorescing and the greatest contrast (brightness) between fluorescing malignant cells and background fluorescence, indicating significant porphyrin uptake in the malignant bodies. Sputum samples processed with HPD and TPPS had moderate porphyrin uptake, and samples process with URO had the least porphyrin uptake.

3. Incubation Time:

Each sputum sample was incubated at 37°C with each of the porphyrins for either 6 or 24 hours and then evaluated for porphyrin uptake with a fluorescent microscope. At the 6 hour incubation period, the cells had begun to localize porphyrin; however, when the sputum cells were washed with PBS, the fluorescence diminished considerably. This suggests that the porphyrin was not firmly bonded to the cells. By 24 hours, by contrast, the uptake of porphyrin by sputum cells increased considerably. This was demonstrated by the number of cells which had taken up porphyrin and the intensity of porphyrin fluorescence. When the sputum cells that had been incubated for 24 hours were washed with PBS, the porphyrin remained attached to the cells. Longer incubation times were not investigated.

4. Uptake In Test And Control Samples:

Control sputum samples did not contain neoplastic cells. However, a large number of inflammatory cells were found to be present. When porphyrin uptake in the test and control samples were compared (i.e., the number of sputum cells which fluoresced), the porphyrin uptake in the

control samples was considerably lower than the uptake in the test samples. In addition, the fluorescence intensity of the few control cells that did fluoresce was lower than the fluorescence intensity of the test cells. The most dramatic difference between the uptake of porphyrin by test and control sputum cells was seen in samples incubated with TCPP.

5. Identification Of Sputum Cells Which Fluoresced:

To assist in the identification of the neoplastic cells, sputum samples which had the greatest TCPP uptake were stained with PAP stain, a stain routinely used by cytologists to identify neoplastic cells. Cells identified as neoplastic using the PAP stain were marked and re-examined for TCPP uptake with a fluorescent microscope. Although the fluorescence intensity of the TCPP had been reduced by the PAP staining procedure, TCPP fluorescence was seen in every neoplastic cell.

B. Localization Of TCPP In Different Types Of Lung Cancers:

Studies were conducted using patients having confirmed squamous cell lung carcinoma, oat cell lung carcinoma, lung adenocarcinoma, and advanced metastatic lymphoma (lung metastasis) using procedures identical to those set forth above. Using as a measure the number of fluorescent cells in a sputum sample times the fluorescence intensity of the cells, it was found that this number was 3-6 times greater for sputum samples from cancer patients than for noncancerous patients. These studies also confirm that TCPP and carbowax and ethanol resulted in the greatest uptake of porphyrin in neoplastic sputum cells.

Further investigations determined that TCPP also localizes in cancers of the lung grown in tissue cultures. Moreover, squamous carcinoma cells grown in culture and treated with TCPP can easily be detected using flow

cytometry, and that autofluorescence of control cells (cells not exposed to TCPP) was negligible when compared to the fluorescence of cells exposed to TCPP. Expanding the investigations to other types of lung cells, it was found that human small cell (oat cell) lung carcinoma absorbed TCPP in 2-3 times lower quantities than did the squamous cell line, but this is still considerably higher than uptake in normal cells. It was also found that normal human lung epithelial cells concentrated TCPP at only slightly above autofluorescence or background levels; that is, at many times lower concentration than that TCPP concentration in the neoplastic cell lines examined. Incubating the cells for 24 hours in TCPP was more than adequate to maximize the TCPP localization, and fixing the cells prior to TCPP exposure increased the TCPP uptake. Paraformaldehyde as a fixant was found to slightly increase the TCPP uptake of the cells over those fixed with alcohol and carbowax.

C. Supportive Investigations Using ^{67}Cu :

1. Production of Copper-67 and Copper-67/Porphyrin Complex:

The production of copper-67 involves the irradiation of a zinc oxide target with 600 to 800 MeV protons for several days. The spallation reaction in the target produces not only ^{67}Cu , but also a several other isotopes of lighter mass than zinc. The purification procedure is complicated and involves the separation of ^{67}Cu from zinc and other metals by electrochemical plating (J. A. Mercer-Smith et al., "The Development Of Copper-67 Labeled Porphyrin-Antibody Conjugates," in Targeted Diagnosis And Therapy, Vol. 1, Antibody-Mediated Delivery Systems; J. T. Rodwell, Ed. (Marcel Dekker, New York, 1988) pp.317-352). Preparation of $^{67}\text{CuTCPP}$ is achieved from either N-bzHTCPP or TCPP by radiometallation with $^{67}\text{CuCl}_2$.

2. Serum Stability of ^{67}Cu TCPP:

An important consideration in the development of a radiopharmaceutical is the stability of the complex ^{67}Cu TCPP to the loss of the radioisotope ^{67}Cu in vivo. To
05 test the stability of ^{67}Cu TCPP, a fluorescence method capitalizing on the fact that copper porphyrins do not fluoresce, while nonmetallated do, was developed by which the loss of copper could be measured under simulated physiological conditions (J. C. Roberts et al.,
10 "Preparation And Characterization Of Copper-67 Porphyrin-Antibody Conjugates," J. Immunol. Methods 105, 153 (1987). It was found that the stability of CuTCPP in human serum albumin, and two chelating agents, EDTA and DTPA was such that less than one percent conversion (the
15 limit of detection) occurred in incubation periods of up to 12 days. In addition, there was no detectable transcomplexation with other metal ions as indicated by ultraviolet-visible spectroscopy.

3. Biodistribution And Biological Half-Life Of ^{67}Cu TCPP:

20 A sterile dose of ^{67}Cu TCPP (1.0×10^{-6} gm) was intravenously injected into the tail vein of rats. It was determined that the liver and kidney of these normal animals (no cancer) were the major organs of ^{67}Cu TCPP
25 localization. From these results, it can be concluded that ^{67}Cu TCPP is suitable for detection and treatment of cancerous lung tissue in vivo, since normal lung tissue does not appear to take up significant quantities of ^{67}Cu TCPP, making lung tumor to normal lung cell uptake
30 ratios substantial. A biological half-life study demonstrated that ^{67}Cu TCPP is biologically eliminated from the animals following a normal exponential decay curve, with a half-life of 108 hours.

The foregoing description of several preferred embodiments of the invention have been presented for purposes of illustration and description. It is not intended to be exhaustive or to limit the invention to the precise form disclosed, and obviously many modifications and variations are possible in light of the above teaching. For example, it would be apparent to one having ordinary skill in the art of cancer detection and treatment after studying the present disclosure that a method for locating the situs of lung malignancies in vivo, could include injecting a sample of the ^{64}Cu complex of 5,10,15,20-tetrakis(4-carboxyphenyl)porphinato into the bloodstream, or directing an aerosol containing this complex into the lungs of a patient to be diagnosed, and performing positron emission tomography (G. Firnaeu et al., " ^{64}Cu Labelling Of Hematoporphyrin Derivative For Non-Invasive In-Vivo Measurements Of Tumour Uptake," in Progress In Clinical And Biological Research, Vol. 170, D. Doiron and C. Gomer, eds.; "Porphyrin Localization And Treatment Of Tumors," pp. 629-636 (1984)). For radioisotope labeling using isotopes having long-half-lives, it would be apparent to an individual having such skill in the relevant art that it would also be effective to introduce the ^{64}Cu complexes into tissue for subsequent diffusion into the bloodstream. It would further be apparent to a practitioner having ordinary skill that samples could be prepared from biopsies of tissue masses as well as from sputum samples for in vitro diagnoses.

The embodiments were chosen and described in order to best explain the principles of the invention and its practical application to, thereby enable others skilled in the art to best utilize the invention in various embodiments and with various modifications as are suited to

the particular use contemplated. It is intended that the scope of the invention be defined by the claims appended hereto.

WHAT IS CLAIMED IS:

1. A method for detecting cancers of the lung, comprising the steps of producing a single cell suspension of lung cells, treating the single cell suspension of lung cells with 5,10,15,20-tetrakis(4-carboxyphenyl)porphine for sufficient time to ensure significant uptake thereof by neoplastic lung cells present in the single cell suspension of lung cells, exposing the treated cell suspension with ultraviolet radiation in order to induce fluorescence in 5,10,15,20-tetrakis(4-carboxyphenyl)porphine taken up by the neoplastic cells, and evaluating the suspension for fluorescing cells.

2. The method as described in Claim 1, wherein said step of treating the single cell suspension with 5,10,15,20-tetrakis(4-carboxyphenyl)porphine includes incubation of the suspension at elevated temperatures.

3. The method as described in Claim 2, wherein said step of treating the single cell suspension further includes fixing the cell sample with carbowax and alcohol.

4. The method as described in Claim 2, wherein said step of treating the single cell suspension further includes fixing the cell sample with paraformaldehyde.

5. The method as described in Claim 1, wherein said step of evaluating the cell suspension for fluorescing cells includes the use of fluorescence imaging techniques, and the suppression of background fluorescence emission.

6. The method as described in Claim 1, wherein said step of treating the single cell suspension further includes thoroughly blending the single cell suspension with 5,10,15,20-tetrakis(4-carboxyphenyl)porphine.

7. The method as described in Claim 1, wherein said step of evaluating the cell suspension for fluorescing cells includes the use of flow cytometry techniques.

8. A method for treating lung cancer, comprising the step of injecting a sample of the ^{67}Cu complex of 5,10,15,20-tetrakis(4-carboxyphenyl)porphinato into the bloodstream of a patient to be treated.

05 9. A method for locating sites of lung malignancies in vivo, comprising the steps of injecting a sample of the ^{67}Cu complex of 5,10,15,20-tetrakis(4-carboxyphenyl)porphinato into the bloodstream of a patient to be treated, and performing image analysis of the emitted gamma radiation.

10. A method for treating lung cancer, comprising the step of directing an aerosol containing the ^{67}Cu complex of 5,10,15,20-tetrakis(4-carboxyphenyl)porphinato into the lungs of a patient to be treated.

05 11. A method for locating sites of lung malignancies in vivo, comprising the steps of directing an aerosol containing the ^{67}Cu complex of 5,10,15,20-tetrakis(4-carboxyphenyl)porphinato into the lungs of a patient to be treated, and performing image analysis of the emitted gamma radiation.

05 12. A method for locating sites of lung malignancies in vivo, comprising the steps of injecting a sample of the ^{64}Cu complex of 5,10,15,20-tetrakis(4-carboxyphenyl)porphinato into the bloodstream of a patient to be treated, and performing positron emission tomography of the emitted positron radiation.

13. A method for locating sites of lung malignancies in vivo, comprising the steps of directing an aerosol containing the ^{64}Cu complex of 5,10,15,20-tetrakis (4-carboxyphenyl)porphinato into the lungs of a patient to
05 be treated, and performing positron emission tomography of the emitted gamma radiation.

14. A method for detecting cancers of the lung, comprising the steps of producing a single cell suspension of lung cells, treating the single cell suspension of lung cells with a tetra-aryl porphyrin for sufficient time to
05 ensure significant uptake thereof by neoplastic lung cells present in the single cell suspension of lung cells, exposing the treated cell suspension with ultraviolet radiation in order to induce fluorescence in 5,10,15,20-tetrakis(4-carboxyphenyl)porphine taken up by the
10 neoplastic cells, and evaluating the suspension for fluorescing cells.

15. The method as described in Claim 14, wherein said step of treating the single cell suspension with a tetra-aryl porphyrin includes incubation of the suspension at elevated temperatures.

16. The method as described in Claim 15, wherein said step of treating the single cell suspension further includes fixing the cell sample with carbowax and alcohol.

17. The method as described in Claim 15, wherein said step of treating the single cell suspension further includes fixing the cell sample with paraformaldehyde.

18. The method as described in Claim 14, wherein said step of evaluating the cell suspension for fluorescing cells includes the use of fluorescence imaging techniques, and the suppression of background fluorescence emission.

19. The method as described in Claim 14, wherein said step of treating the single cell suspension further includes thoroughly blending the single cell suspension with 5,10,15,20-tetrakis(4-carboxyphenyl)porphine.

20. The method as described in Claim 14, wherein said step of evaluating the cell suspension for fluorescing cells includes the use of flow cytometry techniques.

21. A method for treating lung cancer, comprising the step of injecting a sample of the ^{67}Cu complex of a tetra-aryl porphyrin into the bloodstream of a patient to be treated.


22. A method for locating sites of lung malignancies in vivo, comprising the steps of injecting a sample of the ^{67}Cu complex of a tetra-aryl porphyrin into the bloodstream of a patient to be treated, and performing
05 image analysis of the emitted gamma radiation.

23. A method for treating lung cancer, comprising the step of directing an aerosol containing the ^{67}Cu complex of a tetra-aryl porphyrin into the lungs of a patient to be treated.

24. A method for locating sites of lung malignancies in vivo, comprising the steps of directing an aerosol containing the ^{67}Cu complex of a tetra-aryl porphyrin into the lungs of a patient to be treated, and performing
05 image analysis of the emitted gamma radiation.

25. A method for locating sites of lung malignancies in vivo, comprising the steps of injecting a sample of the ^{64}Cu complex of a tetra-aryl porphyrin into the bloodstream of a patient to be treated, and performing
05 positron emission tomography of the emitted positron radiation.

26. A method for locating sites of lung malignancies
in vivo, comprising the steps of directing an aerosol
containing the ^{64}Cu complex of a tetra-aryl porphyrin
into the lungs of a patient to be treated, and performing
05 positron emission tomography of the emitted gamma
radiation.

Figure

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/04132

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC ICP(5): G01N 33/48 U.S.C1: 436/64																	
II. FIELDS SEARCHED <div style="text-align: center; margin-top: 10px;">Minimum Documentation Searched ⁷</div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 20%;">Classification System</th> <th style="width: 80%;">Classification Symbols</th> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">U.S.</td> <td style="padding: 5px;">436/64, 800, 805, 519, 514/410, 185; 435/119, 968</td> </tr> </table> <div style="text-align: center; margin-top: 10px;">Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched ⁸</div> <div style="text-align: center; margin-top: 20px; font-weight: bold;">APS, STN-File Biosis, CA, Medline, Dialog</div>			Classification System	Classification Symbols	U.S.	436/64, 800, 805, 519, 514/410, 185; 435/119, 968											
Classification System	Classification Symbols																
U.S.	436/64, 800, 805, 519, 514/410, 185; 435/119, 968																
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹ <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%;">Category [*]</th> <th style="width: 70%;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 20%;">Relevant to Claim No. ¹³</th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;">Biosis Abstract, volume 51, no. 4, issued 1980, SHULOK et al, "Subcellular Localization of Hematoporphyrin Derivate in Bladder Tumor Cells in culture", pages 451-458, see abstract No. 90:334016.</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1,2,5,6,7,14 15,18,19,20</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;">Biosis Abstract, volume 42, No. 6, Berns et al, "In vitro cellular effects of Hematoporphyrin Derivative," pages 2325-2329, see abstract No. 82:277948.</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1,2,5,6,7,14 15,18,19,20</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;">Biosis Abstract, volume 28, No. 3, issued 1980, Musser et al, "The Binding of Tumor Localizing Porphyrins to a Fibrin Matrix and their effects following photo Irradiation", pages 505-526, see abstract No. 80:266560.</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1,2,5,6,7,14 15,18,19,20</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;">US, A, 4,857,300 (MAKSEM) 15 August 1989, see entire document</td> <td style="text-align: center; vertical-align: top; padding: 5px;">3,4,16,17</td> </tr> </tbody> </table>			Category [*]	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	Y	Biosis Abstract, volume 51, no. 4, issued 1980, SHULOK et al, "Subcellular Localization of Hematoporphyrin Derivate in Bladder Tumor Cells in culture", pages 451-458, see abstract No. 90:334016.	1,2,5,6,7,14 15,18,19,20	Y	Biosis Abstract, volume 42, No. 6, Berns et al, "In vitro cellular effects of Hematoporphyrin Derivative," pages 2325-2329, see abstract No. 82:277948.	1,2,5,6,7,14 15,18,19,20	Y	Biosis Abstract, volume 28, No. 3, issued 1980, Musser et al, "The Binding of Tumor Localizing Porphyrins to a Fibrin Matrix and their effects following photo Irradiation", pages 505-526, see abstract No. 80:266560.	1,2,5,6,7,14 15,18,19,20	Y	US, A, 4,857,300 (MAKSEM) 15 August 1989, see entire document	3,4,16,17
Category [*]	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³															
Y	Biosis Abstract, volume 51, no. 4, issued 1980, SHULOK et al, "Subcellular Localization of Hematoporphyrin Derivate in Bladder Tumor Cells in culture", pages 451-458, see abstract No. 90:334016.	1,2,5,6,7,14 15,18,19,20															
Y	Biosis Abstract, volume 42, No. 6, Berns et al, "In vitro cellular effects of Hematoporphyrin Derivative," pages 2325-2329, see abstract No. 82:277948.	1,2,5,6,7,14 15,18,19,20															
Y	Biosis Abstract, volume 28, No. 3, issued 1980, Musser et al, "The Binding of Tumor Localizing Porphyrins to a Fibrin Matrix and their effects following photo Irradiation", pages 505-526, see abstract No. 80:266560.	1,2,5,6,7,14 15,18,19,20															
Y	US, A, 4,857,300 (MAKSEM) 15 August 1989, see entire document	3,4,16,17															
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>[*] Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>																	
IV. CERTIFICATION <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; padding: 5px;"> Date of the Actual Completion of the International Search <div style="text-align: center; font-weight: bold;">06 September 1991</div> </td> <td style="width: 50%; padding: 5px;"> Date of Mailing of this International Search Report <div style="text-align: center; font-weight: bold; font-size: 1.2em;">02 OCT 1991</div> </td> </tr> <tr> <td style="width: 50%; padding: 5px;"> International Searching Authority <div style="text-align: center;">ISA/US</div> </td> <td style="width: 50%; padding: 5px;"> Signature of Authorized Officer <div style="text-align: center;">Thomas E. Daley</div> </td> </tr> </table>			Date of the Actual Completion of the International Search <div style="text-align: center; font-weight: bold;">06 September 1991</div>	Date of Mailing of this International Search Report <div style="text-align: center; font-weight: bold; font-size: 1.2em;">02 OCT 1991</div>	International Searching Authority <div style="text-align: center;">ISA/US</div>	Signature of Authorized Officer <div style="text-align: center;">Thomas E. Daley</div>											
Date of the Actual Completion of the International Search <div style="text-align: center; font-weight: bold;">06 September 1991</div>	Date of Mailing of this International Search Report <div style="text-align: center; font-weight: bold; font-size: 1.2em;">02 OCT 1991</div>																
International Searching Authority <div style="text-align: center;">ISA/US</div>	Signature of Authorized Officer <div style="text-align: center;">Thomas E. Daley</div>																

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

Y,P	US, A, 4,930,516 (ALFANO et al) 05 June 1990, see entire article.	1,2,5,6,7,14 15,18,18,20
A	US, A, 4,783,529 (LAVALLEE et al) 08 November 1988.	

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers _____, because they relate to subject matter ¹² not required to be searched by this Authority, namely:

2. ☐ Claim numbers _____, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out ¹³, specifically:

3. ☐ Claim numbers _____, because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☒ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This International Searching Authority found multiple inventions in this international application as follows:

- I. Claims 1-7 and 14-20 drawn to an in vitro detecting method, Class 436 Subclass 64; II. Claims 8,9,11,12,13,22,24,26 drawn to an in vivo detecting method, Class 424, Subclass 1.1; III. Claims 10,21,23 drawn to a method of treating ling cancer using a radioactive compound, Class 534, Subclass 10.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☒ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
☐ No protest accompanied the payment of additional search fees.

THIS PAGE BLANK (1877)